LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein

Yang,Zhi; Wang,Zitong; Duan,Yong

doi:10.3892/ol.2020.11770

LncRNA MEG3 inhibits non‑small cell lung cancer via interaction with DKC1 protein

Authors:
- Zhi Yang
- Zitong Wang
- Yong Duan
View Affiliations

Affiliations: Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, P.R. China
Published online on: June 24, 2020 https://doi.org/10.3892/ol.2020.11770
Pages: 2183-2190
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA (lncRNA) MEG3 is a key biomarker and therapeutic target in lung cancer; however, its underlying molecular mechanism in lung cancer progression remains unclear. The present study demonstrated a novel regulatory axis in lung cancer, lncRNA MEG3/dyskeratosis congenita 1 (DKC1), and further investigated the effects and molecular mechanism of lncRNA MEG3/DKC1 in lung cancer. RT‑qPCR and western blot analysis were performed to determine gene and protein expression levels. The RNA immunoprecipitation assay was performed to verify binding between lncRNA MEG3 and DKC1. Flow cytometry analysis was performed to assess cell apoptosis, while the Cell Counting Kit‑8 assay was performed to determine cell viability. Transwell and wound healing assays were performed to assess cell invasion and migration, respectively. Telomerase activity was measured using the quantitative TeloTAGGG Telomerase PCR‑ELISA kit. The results demonstrated that lncRNA MEG3 was downregulated, while its binding protein, DKC1, was upregulated in lung cancer cells. Furthermore, lncRNA MEG3 inhibited cell proliferation, migration, invasion and telomerase activity in A549 cells by downregulating DKC1. lncRNA MEG3 inhibited non‑small cell lung cancer progression by inhibiting telomere function, cell proliferation, telomerase activity, cell migration and invasion via regulation of the DKC1 protein expression. LncRNA MEG3/DKC1 was identified as a novel dual‑directional regulatory axis in the present study, acting as a promising target for the treatment of lung cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Shen M and Xu Z, Jiang K, Xu W, Chen Y and Xu Z: Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non-small cell lung caner. Tumor Biol. 39:10104283176959482017. View Article : Google Scholar
3	Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY, Chen LA, Li WM, Li SY, Wang K, Wang Q, et al: Prevention and management of lung cancer in China. Cancer. 121 (Suppl 17):S3080–S3088. 2015. View Article : Google Scholar
4	Shu J, Wang L, Han F, Chen Y, Wang S and Luo F: BTBD7 Downregulates E-cadherin and promotes epithelial-mesenchymal transition in lung cancer. Biomed Res Int. 2019:59376352019. View Article : Google Scholar : PubMed/NCBI
5	Hoffman RM and Sanchez R: Lung cancer screening. Med Clin North Am. 101:769–785. 2017. View Article : Google Scholar : PubMed/NCBI
6	O'Dowd EL and Baldwin DR: Early diagnosis pivotal to survival in lung cancer. Practitioner. 258:21–24, 2-3. 2014.
7	Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC and Han PKJ: Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer. 112:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
8	Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP and Oxnard GR: Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. Lung Cancer. 122:72–75. 2018. View Article : Google Scholar : PubMed/NCBI
9	Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R and Oudkerk M: Complication rates of CT-guided transthoracic lung biopsy: Meta-analysis. Eur Radiol. 27:138–148. 2017. View Article : Google Scholar : PubMed/NCBI
10	Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
11	Shi YX, Sheng DQ, Cheng L and Song XY: Current landscape of epigenetics in lung cancer: Focus on the mechanism and application. J Oncol. 2019:81073182019. View Article : Google Scholar : PubMed/NCBI
12	Jathar S, Kumar V, Srivastava J and Tripathi V: Technological developments in lncRNA biology. Adv Exp Med Biol. 1008:283–323. 2017. View Article : Google Scholar : PubMed/NCBI
13	Chen R, Li WX, Sun Y, Duan Y, Li Q, Zhang AX, Hu JL, Wang YM and Gao Y: Comprehensive analysis of lncRNA and mRNA expression profiles in lung cancer. Clin Lab. 63:313–320. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wei GH and Wang X: lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
15	Zhou Y, Zhang X and Klibanski A: MEG3 noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhou Y, Yang H, Xia W, Cui L, Xu R, Lu H, Xue D, Tian Z, Ding T, Cao Y, et al: LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2. J Biochem. 167:295–301. 2019. View Article : Google Scholar
17	Zhu X, Zhang HW, Chen HN, Deng XJ, Tu YX, Jackson AO, Qing JN, Wang AP, Patel V and Yin K: Perivascular adipose tissue dysfunction aggravates adventitial remodeling in obese mini pigs via NLRP3 inflammasome/IL-1 signaling pathway. Acta Pharmacol Sin. 40:46–54. 2019. View Article : Google Scholar : PubMed/NCBI
18	Wu JL, Meng FM and Li HJ: High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p. Eur Rev Med Pharmacol Sci. 22:5938–5945. 2018.PubMed/NCBI
19	Zhang Z, Liu T, Wang K, Qu X, Pang Z, Liu S, Liu Q and Du J: Down-regulation of long non-coding RNA MEG3 indicates an unfavorable prognosis in non-small cell lung cancer: Evidence from the GEO database. Gene. 630:49–58. 2017. View Article : Google Scholar : PubMed/NCBI
20	Terashima M, Tange S, Ishimura A and Suzuki T: MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem. 292:82–99. 2017. View Article : Google Scholar : PubMed/NCBI
21	Ferrè F, Colantoni A and Helmer-Citterich M: Revealing protein-lncRNA interaction. Brief Bioinform. 17:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fernandez-Garcia I, Marcos T, Muñoz-Barrutia A, Serrano D, Pio R, Montuenga LM and Ortiz-de-Solorzano C: Multiscale in situ analysis of the role of dyskerin in lung cancer cells. Integr Biol (Camb). 5:402–413. 2013. View Article : Google Scholar : PubMed/NCBI
23	Penzo M, Ludovini V, Treré D, Siggillino A, Vannucci J, Bellezza G, Crinò L and Montanaro L: Dyskerin and TERC expression may condition survival in lung cancer patients. Oncotarget. 6:21755–21760. 2015. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kulić A, Plavetić ND, Gamulin S, Jakić-Razumović J, Vrbanec D and Sirotković-Skerlev M: Telomerase activity in breast cancer patients: Association with poor prognosis and more aggressive phenotype. Med Oncol. 33:232016. View Article : Google Scholar : PubMed/NCBI
26	Loewen G, Jayawickramarajah J, Zhuo Y and Shan B: Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol. 7:902014. View Article : Google Scholar : PubMed/NCBI
27	Tan BS, Yang MC, Singh S, Chou YC, Chen HY, Wang MY, Wang YC and Chen RH: LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 38:5612–5626. 2019. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y, Feng C, Li Y, Ma Y and Cai R: LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function. Mol Cell Biochem. 460:1–8. 2019. View Article : Google Scholar : PubMed/NCBI
29	Xia H, Qu XL, Liu LY, Qian DH and Jing HY: LncRNA MEG3 promotes the sensitivity of vincristine by inhibiting autophagy in lung cancer chemotherapy. Eur Rev Med Pharmacol Sci. 22:1020–1027. 2018.PubMed/NCBI
30	Zhao Y, Zhu Z, Shi S, Wang J and Li N: Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis. Biomed Pharmacother. 120:1094572019. View Article : Google Scholar : PubMed/NCBI
31	Zhang M, Pan Y, Jiang R, Hou P, Shan H, Chen F, Jiang T, Bai J and Zheng J: DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF-κB pathway. Oncol Rep. 40:968–978. 2018.PubMed/NCBI
32	Liu B, Zhang J, Huang C and Liu H: Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One. 7:e431472012. View Article : Google Scholar : PubMed/NCBI
33	Nersisyan L, Hopp L, Loeffler-Wirth H, Galle J, Loeffler M, Arakelyan A and Binder H: Telomere length maintenance and its transcriptional regulation in lynch syndrome and sporadic colorectal carcinoma. Front Oncol. 9:11722019. View Article : Google Scholar : PubMed/NCBI
34	Richards LA, Kumari A, Knezevic K, Thoms JA, von Jonquieres G, Napier CE, Ali Z, O'Brien R, Marks-Bluth J, Maritz MF, et al: DKC1 is a transcriptional target of GATA1 and drives upregulation of telomerase activity in normal human erythroblasts. Haematologica. 105:1517–1526. 2020. View Article : Google Scholar : PubMed/NCBI
35	Bernardes de Jesus B and Blasco MA: Telomerase at the intersection of cancer and aging. Trends Gene. 29:513–520. 2013. View Article : Google Scholar
36	Mizukoshi E and Kaneko S: Telomerase-targeted cancer immunotherapy. Int J Mol Sci. 20:18232019. View Article : Google Scholar
37	Yuan X, Larsson C and Xu D: Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players. Oncogene. 38:6172–6183. 2019. View Article : Google Scholar : PubMed/NCBI
38	Miao FA, Chu K, Chen HR, Zhang M, Shi PC, Bai J and You YP: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion. Invest New Drugs. 37:1177–1186. 2019. View Article : Google Scholar : PubMed/NCBI
39	Penzo M, Casoli L, Ceccarelli C, Treré D, Ludovini V, Crinò L and Montanaro L: DKC1 gene mutations in human sporadic cancer. Histol Histopathol. 28:365–372. 2013.PubMed/NCBI